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Flaws in the design of randomized trials may bias intervention effect estimates and increase between-trial het-
erogeneity. Empirical evidence suggests that these problems are greatest for subjectively assessed outcomes.
For the Risk of Bias in Evidence Synthesis (ROBES) Study, we extracted risk-of-bias judgements (for sequence
generation, allocation concealment, blinding, and incomplete data) from a large collection of meta-analyses pub-
lished in the Cochrane Library (issue 4; April 2011). We categorized outcome measures as mortality, other objec-
tive outcome, or subjective outcome, and we estimated associations of bias judgements with intervention effect
estimates using Bayesian hierarchical models. Among 2,443 randomized trials in 228 meta-analyses, intervention
effect estimates were, on average, exaggerated in trials with high or unclear (versus low) risk-of-bias judgements
for sequence generation (ratio of odds ratios (ROR) = 0.91, 95% credible interval (CrI): 0.86, 0.98), allocation con-
cealment (ROR= 0.92, 95%CrI: 0.86, 0.98), and blinding (ROR= 0.87, 95%CrI: 0.80, 0.93). In contrast to previous
work, we did not observe consistently different bias for subjective outcomes compared with mortality. However, we
found an increase in between-trial heterogeneity associated with lack of blinding in meta-analyses with subjective
outcomes. Inconsistency in criteria for risk-of-bias judgements applied by individual reviewers is a likely limitation
of routinely collected bias assessments. Inadequate randomization and lack of blinding may lead to exaggeration
of intervention effect estimates in randomized trials.
allocation concealment; bias; blinding; meta-analysis; missing data; randomization; randomized trials
Abbreviations: BRANDO, Bias in Randomized and Observational Studies; CrI, credible interval; IQR, interquartile range; MRC,
Medical Research Council; ROBES, Risk of Bias in Evidence Synthesis; ROR, ratio of odds ratios; SD, standard deviation.
Meta-analyses of randomized trials are often more influential
than single trials, and they increasingly inform health-care deci-
sions made by clinicians and health authorities. For their results
to be valid, randomized trials should employ rigorous methods
that can achieve and preserve comparability of the intervention
and control groups (1). For example, concealment of random-
ized allocation prevents an influence of patient characteristics
on allocation to intervention and control groups; blinding of
participants and trial personnel prevents differences in patient
management between groups; and blinding of outcome asses-
sors prevents knowledge of the assigned intervention group
influencing outcome measurement. Randomized trials vary in
methodological rigor, and flaws in trial conduct can lead to
biased estimation of the intervention effect (2). Systematic
reviewers should therefore assess the risk of bias in inter-
vention effect estimates from each included trial.
Meta-epidemiologic studies analyze collections of meta-
analyses to provide empirical evidence about the influence
of trial design characteristics on trial results (3). Such studies
have, however, reached differing conclusions about which
trial design characteristics most influence their results (4–8).
For example, 4 studies found that lack of adequate allocation
concealment was associated with overestimation of treatment
effect (9–12), while several other studies did not find evidence
for this (4, 5, 13–15). In a previous study, we explored reasons
for these discrepancies by combining data from 7 meta-
epidemiologic studies (16, 17). To our knowledge, this was
the first study to explore the effects of bias on between– and
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within–meta-analysis heterogeneity using Bayesian hierar-
chical models. The results suggested that trial results based on
subjectively assessed outcomes are more susceptible to bias
and that the effect of bias is unpredictable, leading to increased
heterogeneity in meta-analyses assessing subjective outcomes
(16, 17). Further investigation of the effects of trial character-
istics across different interventions, settings, and outcomes in
larger collections of meta-analyses (not previously used) may
provide more clarity and resolve inconsistencies between pre-
vious empirical studies.
Since January 2008, authors of Cochrane reviews have used
a “risk-of-bias” tool for assessing included trials (18). The
assessorsmake judgements in relation to “sequence generation,”
“allocation concealment,” “blinding of participants, personnel,
and outcome assessors,” “incomplete outcome data,” “selective
outcome reporting,” and a general category of “other potential
threats to validity.” For each of these areas, review authors
record whether there was a judgement of low, high, or unclear
risk of bias for each trial, together with comments or quotes to
justify each judgement. Accumulated standardized risk-of-
bias assessments are a potentially useful resource for meta-
epidemiologic research.
In this paper, we describe and report the main results from a
new, large empirical study investigating the associations of
risk-of-bias judgements for sequence generation, allocation
concealment, blinding, and incomplete outcome data with
treatment effect estimates— the Risk of Bias in Evidence Syn-
thesis (ROBES) Study. Our aims were to examine whether
routinely collected risk-of-bias assessments relating to meth-
odological characteristics are associated with effect estimates,
to compare these associations with findings from our previous
study (17), and to examine further the effect of outcome types
in a new collection of meta-analyses.
METHODS
Data source
TheApril 2011 issue of the Cochrane Database of Systematic
Reviews (issue 4) included 4,371 intervention reviews (exclud-
ing protocols), of which 1,399 had at least 2 completed domains
in the Risk of Bias tables. The complete 1,399 reviews were
supplied by the Cochrane Informatics and Knowledge Manage-
ment Department in electronic format, as ReviewManager (ver-
sion 5.0) files (19).We converted these to a customizedMicrosoft
Access database (Microsoft Corporation, Redmond,Washington)
using bespoke software whichwe commissioned fromRiskaware
Ltd. (Bristol, UnitedKingdom).
Data selection and categorization
We selected meta-analyses that fulfilled the following criteria:
1) address a binary outcome; 2) include at least 5 randomized
trials, eachwith at least 1 event across the 2 trial arms; 3) accom-
panied by risk-of-bias assessments, with all 5 core domains
of the tool having been assessed (sequence generation, alloca-
tion concealment, blinding, incomplete outcome data, and selec-
tive outcome reporting); 4) compare an active intervention with
a control or “older” intervention; and 5) include no trials that
overlap with another meta-analysis in the data set. Details of the
process for selecting eligible meta-analyses are provided in
Web Appendix 1 (available at https://academic.oup.com/aje).
Meta-analyses can inform estimation of the bias associated with
a particular domain only if they contain at least 1 trial at “low
risk” of bias and 1 at “high or unclear” risk of bias. We refer
to these as informativemeta-analyses for that bias domain.
We categorized each meta-analysis according to objectiv-
ity of the outcome measure (see below), direction of outcome
(adverse or favorable) (16, 17), type of intervention (pharmaco-
logical, surgical, psychosocial and behavioral, care pathways, or
other), clinical area (based on the World Health Organization’s
International Classification of Diseases, Tenth Revision) (20),
and whether the comparator was an active intervention (i.e., not
a placebo, untreated, or standard care). Classification of out-
come measure objectivity followed the method of Savovic´ et al.
(16, 17):We categorized outcomemeasures as 1) all-cause mor-
tality; 2) other objectively assessed outcome (including live
birth, noncephalic birth, low birth weight, miscarriage, preg-
nancy, and all automated laboratory outcomes); 3) semiobjec-
tive outcome (where the outcome event is considered to be
measured accurately but the decision behind it is influenced by
a clinician’s or patient’s judgement (e.g., hospital admission or
readmission, study dropout/withdrawal for any reason, treat-
ment completion, cesarean delivery, spontaneous vaginal birth,
operative/assisted delivery, conversion to open surgery, addi-
tional treatments administered)); or 4) subjectively assessed
outcome (e.g., clinician-assessed outcomes, symptoms and
symptom scores, pain, mental health outcomes, cause-specific
mortality). Too few meta-analyses had outcomes in the objec-
tive and semiobjective categories (categories 2 and 3) for sepa-
rate analyses to be possible, so we combined these categories as
“other objective.”When both objective and subjective methods
of outcome assessment were used in different trials contributing
to the samemeta-analysis, the meta-analysis was categorized as
having a subjectively assessed outcome (e.g., some trials in meta-
analyses examining smoking cessation used a laboratorymeasure,
while others used patient self-reporting).
Statistical analysis
To explore correlations between bias domains, we computed
odds ratios for the association between risk-of-bias judgements
for pairs of domains using logistic regression in Stata 14 (Stata-
Corp LP, College Station, Texas). For the main analyses, we
modeled intervention effects as log odds ratios with outcomes
coded so that odds ratios less than 1 corresponded to beneficial
intervention effects in all meta-analyses. In the main analysis,
“high risk” and “unclear risk” bias judgements were grouped
together. The underlying idea of the analysis is described in
Web Appendix 2 and illustrated in Web Figure 1.
We fitted Bayesian hierarchical bias models, assuming a
binomial likelihood (“model 3” byWelton et al. (21)). This as-
sumes random intervention effects (between-trial heterogene-
ity) within meta-analyses, which allows us to assess whether
individual bias domains are associated with increased heteroge-
neity. The model includes parameters for average bias in inter-
vention effects (log odds ratios comparing trials at “high or
unclear” risk of bias with “low” risk of bias, averaged across all
meta-analyses) and 2 sources of variation in bias. Variation in
bias among trials within meta-analyses was quantified using a
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κ2 term representing the average increase in between-trial het-
erogeneity in trials at “high or unclear” risk of bias (vs. “low”
risk of bias) for each bias domain. Variation in mean bias
across meta-analyses was quantified by a measure of between–
meta-analysis variance, φ2. Posterior mean values for aver-
age bias were exponentiated and are reported as the ratio of
odds ratios; posterior median values for κ and φ are reported
on the log odds ratio scale. All are presented with 95% credi-
ble intervals. Meta-analyses containing fewer than 2 studies at
“low risk” of bias and at “high or unclear” risk of bias are
uninformative for κ and thus were prevented from influencing
the estimation of this parameter. Additional statistical analysis
information and analysis code is provided in Web Appen-
dix 2.
We conducted univariable analyses for each of 4 risk-of-
bias domains (sequence generation, allocation concealment,
blinding, and incomplete outcome data) using all informative
meta-analyses for that domain (model A inWeb Appendix 2).
We did not explore the association between the selective out-
come reporting domain and intervention effect estimates. This
domain currently addresses the nonreporting of outcomes
rather than bias in the results available for meta-analysis, so it
is not directly relevant to bias in the observed results. Analyses
were also stratified according to type of outcomemeasure (all-
cause mortality, other objectively assessed, and subjectively
assessed). Multivariable analyses were based on an extended
model assuming distinct variance components associated with
each bias domain (model B in Web Appendix 2), described
elsewhere by Savovic´ et al. (16). We also fitted multivariable
analyses that allowed interactions between sequence genera-
tion and allocation concealment, allocation concealment and
blinding, and sequence generation and blinding (model C
in Web Appendix 2). We conducted a univariable sensitivity
analysis combining trials with an “unclear” risk-of-bias judge-
ment with those with “low risk” of bias (rather than with “high
risk”). We also conducted separate analyses for objective and
semiobjective outcomes.
RESULTS
Following our selection process, the final ROBES Study
data set consisted of 228 meta-analyses containing 2,443 ran-
domized trials (Figure 1). The full list of included reviews and
meta-analysis is provided in Web Appendix 3. The median year
of publication of included reviews was 2008 (interquartile range
(IQR), 2005–2010; range, 1996–2011), and for trials it was 1999
(IQR, 1992–2005, range, 1950–2011). The median sample size
was 1,290 (IQR, 676–3,403; range, 110–341,351) for meta-
analyses and 114 (IQR, 60–256; range, 8–182,000) for trials.
Based on the categorization of clinical areas in the International
Classification of Diseases, Tenth Revision, the most frequently
assessed conditions were related to pregnancy and childbirth
(28 meta-analyses; 12.3%) andmental health (27 meta-analy-
ses; 11.8%), followed by circulatory system conditions (21
meta-analyses; 9.2%) and respiratory system conditions (20
meta-analyses; 8.8%). Subjectively assessed outcomes were re-
portedmost frequently, in 127 (55.7%)meta-analyses, followed
by all-cause mortality (42meta-analyses; 18.4%) (Table 1).
The proportion of trials judged as being at low risk of bias
was highest for the incomplete outcome data domain (1,493
trials; 61.1%), followed by sequence generation (1,143 trials;
46.8%), blinding (1,119 trials; 45.8%), and allocation conceal-
ment (1,033 trials; 42.3%). The proportion of trials with unclear
risk of bias was highest for allocation concealment (1,267 trials;
51.9%) and sequence generation (1,226 trials; 50.2%) and was
markedly lower for blinding (641 trials; 26.2%) and incomplete
outcome data (580 trials; 23.7%). The proportion of trials rated
as being at high risk of bias was highest for blinding (683 trials;
28.0%), followed by incomplete outcome data (370 trials;
15.2%), with low proportions rated as high risk for alloca-
tion concealment (143 trials; 5.9%) and sequence generation
(74 trials; 3.0%) (Table 2). Numbers of trials with each combi-
nation of the 4 risk-of-bias domain judgements are shown by
type of outcome inWeb Figure 2.
For sequence generation, 2,158 trials were included in 189
(82.9%) informative meta-analyses, of which 1,006 (46.6%)
were judged as having low risk of bias, 1,081 (50.1%) as having
unclear risk of bias, and 71 (3.3%) as having high risk of bias.
For allocation concealment, 2,121 trials were included in
188 (82.5%) informative meta-analyses, of which 933 (44.0%)
were judged as having low, 1,068 (50.3%) as having unclear,
and 120 (5.7%) as having high risk of bias. Only 144 (63.2%)
meta-analyses (1,678 trials) were informative for blinding:
854 (50.9%) trials were judged as low, 437 (26.0%) as unclear,
and 387 (23.1%) as high risk of bias. For incomplete outcome
data, 1,956 trials were included in 167 (73.2%) informative
meta-analyses: 1,156 (59.1%) were judged as low, 475 (24.3%)
as unclear, and 325 (16.6%) as high risk of bias.
There was a strong association between judgements of low
risk of bias for sequence generation and allocation concealment
(odds ratio = 10.4, 95% confidence interval: 8.6, 12.5) (Table 3).
Odds ratios for this association were consistent across types of
outcome variables. Associations between low-risk-of-bias judge-
ments for the other 5 pairs of domains were of smaller magnitude;
odds ratios across all trials varied between 1.8 and 2.9 (Table 3).
Table 4 and Web Figure 3 show results from univariable
analyses (based on model A). Intervention effect estimates
were exaggerated by an average of 9% in trials judged as
being at high or unclear risk of bias for sequence generation
(ratio of odds ratios (ROR) = 0.91, 95% credible interval (CrI):
0.86, 0.98). There was only a modest increase in between-
trial heterogeneity among such trials compared with trials at
low risk of bias (standard deviations (SDs) differed by 0.09
(95% CrI: 0.02, 0.21)). Mean bias varied between meta-
analyses, although this variability was imprecisely esti-
mated (SD, 0.10 (95% CrI: 0.02, 0.20); Table 4). There was
no convincing evidence that the magnitude of average bias dif-
fered according to the type of outcome.Meta-analyses with sub-
jective outcomes contributed the most data to the analysis,
and the average bias among these studies was similar to the
overall result (ROR = 0.90, 95% CrI: 0.83, 0.98). Inmultivari-
able analyses (based on model B), the association between risk-
of-bias judgement and intervention effect estimate was attenu-
ated after adjusting for risk-of-bias judgements for allocation
concealment, blinding, and incomplete outcome data (ROR =
0.95, 95%CrI: 0.89, 1.03). The average bias was similar across
all outcome types (Table 5,Web Figure 4).
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Because there was a strong association between sequence
generation and allocation concealment, the estimates of aver-
age bias for these 2 domains may be expected to be similar.
Intervention effect estimates were exaggerated by an average
of 8% (ROR = 0.92, 95% CrI: 0.86, 0.98) in trials judged to
be at high or unclear risk of bias for allocation concealment,
but there was very little evidence of an increase in between-
trial heterogeneity (SDs differed by 0.05 (95% CrI: 0.01,
0.15)). The variability in average bias across meta-analyses
was small (SD, 0.05 (95% CrI: 0.01, 0.17)). There was little
Meta-Analyses Removed (n = 18,521)
Meta-analyses with <5 trials (n = 17,056)
No events in either intervention arm across all trials (n = 43)
No summary estimate for meta-analysis (n = 12)
Nonbinary data (n = 738)
Unclear which intervention was experimental (n = 589)
Included in the BRANDO Study (n = 83)
Removal of Meta-Analyses That Overlapped With “Selected”
Meta-Analyses (n = 1,562)
Included Data
Systematic reviews (n = 211)
Meta-analyses (n = 228)
Trials (n = 2,428)
Trial results (n = 2,443)
Trial Results Removed From Included Meta-Analyses (n = 361)
Control group of multiple-arm trial repeated (n = 2)
Nonrandomized study (n = 3)
Result already included within another review (n = 12)
Result repeated across subgroups within meta-analysis (n = 52)
Crossover trials (same patients in both groups) (n = 2)
Results with no events in either intervention arm (n = 290)
Removal of Meta-Analyses That Overlapped With Another
Meta-Analysis From Another Review (n = 8)
Supplied Data
Systematic reviews (n = 1,399)
Meta-analyses (n = 29,659)
Data Remaining
Systematic reviews (n = 242)
Meta-analyses “selected” (n = 264)
Data Remaining
Systematic reviews (n = 815)
Meta-analyses (n = 20,347)
Data Remaining
Systematic reviews (n = 242) 
Meta-analyses (n = 1,826)
Data Remaining
Systematic reviews (n = 239)
Meta-analyses (n = 256)
Meta-Analysis Subgroups Removed Because Only Subgroup-Level
Summary Estimates Were Provided (1 Subgroup Kept per
Meta-Analysis) (n = 769)
Trials With 2 Results Each Within a Meta-Analysis Were Kept
When There Was No Patient Overlap Between Them (n = 15)
Meta-Analyses With <5 Trials Removed Because of the Above
Trial Exclusions (n = 28), Resulting in Exclusion of 82 Further Trial
Results and 28 Reviews
Systematic Reviews Removed Because Not All 5 Risk-of-Bias
Domains Were Activated (n = 584)
Systematic Reviews Removed Because of the Above Removal of
Meta-Analyses (n = 573)
Systematic Reviews Removed Because of the Above Removal of
Meta-Analyses (n = 3)
Figure 1. Selection of systematic reviews and meta-analyses from the Cochrane Database of Systematic Reviews (issue 4; April 2011) for inclu-
sion in the ROBESStudy. ROBES, Risk of Bias in Evidence Synthesis.
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Table 1. Characteristics of Meta-Analyses and Randomized Trials Included in the ROBESStudy, 2011–2015
Characteristic
Meta-Analyses
(n = 228)
Randomized Trials
(n = 2,443)
No. % No. %
Clinical area, by ICD-10 chapter
Pregnancy and childbirth 28 12.3 387 15.8
Mental and behavioral disorders 27 11.8 286 11.7
Circulatory system diseases 21 9.2 259 10.6
Respiratory system diseases 20 8.8 196 8.0
Genitourinary system diseases 19 8.3 214 8.8
Perinatal conditions 18 7.9 155 6.3
Digestive system diseases 17 7.5 193 7.9
Infectious and parasitic diseases 11 4.8 113 4.6
Neoplasms 11 4.8 103 4.2
Nervous system diseases 10 4.4 102 4.2
Injury and poisoning 10 4.4 98 4.0
Other ICD-10 chapters 34 14.9 319 13.1
Unclassified 2 0.9 18 0.7
Type of experimental intervention
Pharmacological 151 66.2 1,688 69.1
Provision of care 14 6.1 111 4.5
Surgical intervention or procedure 12 5.3 126 5.2
Psychosocial and behavioral 11 4.8 125 5.1
Other 40 17.5 393 16.1
Type of comparison intervention
Pharmacological 26 11.4 251 10.3
Surgical intervention or procedure 8 3.5 99 4.1
Other active intervention 4 1.8 33 1.4
Placebo/no treatmenta 58 25.4 677 27.7
Placebo 51 22.4 560 22.9
Standard/usual care 32 14.0 307 12.6
No treatment 25 11.0 233 9.5
Standard care/placebo/no treatmenta 24 10.5 283 11.6
Type of outcomemeasureb
All-causemortality 42 18.4 429 17.6
Other objective outcome 20 8.8 197 8.1
Subjective outcome 127 55.7 1,356 55.5
Mixture of objective and subjective outcomesa 2 0.9 70 2.9
Semiobjective outcome 37 16.2 391 16.0
Abbreviations: ICD-10, International Classification of Diseases, Tenth Revision; ROBES, Risk of Bias in Evidence
Synthesis.
a Combined at themeta-analysis level.
b Other objective outcome: automated or semiautomated laboratory measures including biochemical measurements
and serological tests, birth weight, live birth, preterm birth, clinical pregnancy, unintended pregnancy, and noncephalic birth.
Subjective outcome: signs and symptoms of disease and improvement thereof, symptom scales and scores,mental health
outcomes, imaging and radiological outcomes, pain, quality of life, adverse treatment events, other patient-reported out-
comes or those relying on a diagnosis by a physician, and cause-specific deaths.Mixture of objective and subjective out-
comes: meta-analyses in which some trials used laboratory validation while others used self-reporting for smoking
cessation. Semiobjective outcome (outcomes for which ascertainment is accurate but their occurrence is influenced by a
patient’s or care-provider’s subjective judgement): blood transfusion, prescription of antiplatelet medication, cesarean deliv-
ery, spontaneous vaginal birth, preterm birth, oxytocin augmentation, failure of extubation, surgical evacuation, conversion
to open surgery, need for further surgery, radical resection, hospital admission, admission to neonatal intensive care unit,
hospital readmission, presentation at emergency department, compliance with intervention, completion of the study, with-
drawal or dropout from the study, discontinuation of treatment, and not remaining in contact with psychiatric services.
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evidence that the average bias varied according to type of out-
come. Estimates of both between-trial and between–meta-analysis
heterogeneity in bias were low for all outcome types. As for
sequence generation, the analysis including adjustment for
the other 3 domains (model B) produced an attenuated estimate
of average bias (ROR = 0.96, 95%CrI: 0.88, 1.03), and the esti-
mates were very similar across all outcome types (Table 5, Web
Figure 4).
Intervention effect estimates were exaggerated by an average
of 13% (ROR = 0.87, 95% CrI: 0.80, 0.93) in trials judged to
be at high or unclear risk of bias for blinding. Between-trial het-
erogeneity was modestly increased for such studies (SDs dif-
fered by 0.10 (95% CrI: 0.02, 0.25)), and average bias varied
between meta-analyses (SD, 0.12 (95% CrI: 0.02, 0.24)). There
was little evidence that intervention effects differed according
to type of outcome. Increases in between-trial heterogeneity
(SDs differed by 0.22 (95% CrI: 0.04, 0.36)) and between–
meta-analysis heterogeneity in average bias (SD, 0.19 (95%
CrI: 0.03, 0.34)) appeared greater in meta-analyses asses-
sing subjective outcomes than for all-cause mortality or
other objective outcomes. In adjusted analysis (model B), the
estimated effect of high or unclear risk of bias due to blinding
was similar to the unadjusted estimate (ROR = 0.88, 95% CrI:
0.81, 0.94).
There was little evidence that intervention effects were exag-
gerated in trials judged to be at high or unclear risk of bias for
incomplete outcome data (ROR = 0.98, 95% CrI: 0.92, 1.05).
The corresponding estimated increase in between-trial hetero-
geneity was small (SDs differed by 0.05 (95%CrI: 0.01, 0.15)).
Therewas little evidence that average bias or increases in between-
trial heterogeneity varied according to type of outcome. The
adjusted estimates were very similar to the unadjusted estimates
(Table 5,Web Figure 4).
The results of the sensitivity analysis (model A) in which
trials with an unclear risk-of-bias judgement were combined
with those at low risk of bias are shown in Web Table 1. The
average intervention effects in meta-analyses with high risk of
bias for blinding compared with those with low or unclear risk
of bias were exaggerated, on average, by 13% (ROR = 0.87,
95% CrI: 0.79, 0.95), consistent with the main analysis. For the
other 3 bias domains, the 95% credible intervals for estimates of
average bias included the null. These analyses included fewer
informative meta-analyses, especially for sequence generation
and allocation concealment, and consequently the estimates had
wider credible intervals. Estimated increases in between-trial
heterogeneity were larger for sequence generation, compared
with those observed in the main analysis.
The separate estimates for subgroups of meta-analyses
with “other objective” and “semiobjective” outcomes (which
were analyzed together in the main analysis) were similar to
each other for allocation concealment and blinding. They dif-
fered somewhat for sequence generation (ROR = 0.85 (95%
CrI: 0.67, 1.09) for other objective outcomes and ROR =
1.08 (95% CrI: 0.91, 1.34) for semiobjective outcomes) and
incomplete outcome data (ROR = 0.94 (95% CrI: 0.72, 1.22)
for other objective outcomes and ROR = 1.11 (95% CrI: 0.93,
1.30) for semiobjective outcomes), but the credible intervals
were wide and overlapping (Web Table 2).
Table 2. Numbers and Percentages of Randomized Trials Included
in the ROBESStudy, by Risk-of-Bias Judgement
Risk-of-Bias Domain
Risk of Bias
Low High Unclear
No. % No. % No. %
Sequence generation 1,143 46.8 74 3.0 1,226 50.2
Allocation concealment 1,033 42.3 143 5.9 1,267 51.9
Blinding 1,119 45.8 683 28.0 641 26.2
Incomplete outcome
data
1,493 61.1 370 15.2 580 23.7
Abbreviation: ROBES, Risk of Bias in Evidence Synthesis.
Table 3. EstimatedOdds Ratios for the Associations Between Risk-of-Bias Judgements in Randomized Trials Included in the ROBESStudy
Risk-of-Bias Domain Pair
All Trials
(n = 2,443)
All-Cause
Mortality
(n = 429)
Other Objective
Outcome
(n = 197)
“Semiobjective”
Outcomea
(n = 391)
Subjective
Outcomeb
(n = 1,426)
OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Sequence generation, allocation
concealment
10.4 8.6, 12.5 11.3 7.1, 17.9 16.7 7.9, 34.9 9.7 6.1, 15.4 9.5 7.4, 12.2
Sequence generation, blinding 2.5 2.2, 3.0 3.1 2.1, 4.6 2.0 1.0, 3.8 2.2 1.5, 3.3 2.8 2.2, 3.4
Sequence generation, incomplete
outcome data
2.1 1.8, 2.4 2.7 1.8, 4.0 5.3 2.8, 9.8 1.7 1.1, 2.6 1.8 1.4, 2.2
Allocation concealment, blinding 2.9 2.4, 3.4 4.0 2.7, 6.0 6.0 3.0, 12.1 1.3 0.8, 1.9 3.2 2.6, 4.1
Allocation concealment, incomplete
outcome data
2.2 1.8, 2.6 2.9 1.9, 4.4 4.4 2.4, 8.3 1.3 0.9, 2.0 2.0 1.6, 2.5
Blinding, incomplete outcome data 1.8 1.5, 2.1 1.8 1.2, 2.6 1.4 0.7, 2.6 2.1 1.4, 3.2 1.8 1.5, 2.3
Abbreviations: CI, confidence interval; OR, odds ratio; ROBES, Risk of Bias in Evidence Synthesis.
a Outcomes for which ascertainment is accurate but their occurrence is influenced by a patient’s or health-care provider’s subjective judgement
(e.g., duration of hospital stay, admissions, withdrawals, cesarean delivery).
b Includes meta-analyses in which some trials had subjective measures and some objective measures (e.g., self-reports and laboratory
measures).
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In multivariable models with interaction terms (model C),
an interaction was observed between allocation concealment
and blinding (ROR = 0.84, 95%CrI: 0.74, 0.96) and between
sequence generation and blinding (ROR = 0.77, 95% CrI:
0.66, 0.91) (Web Table 3). This means that lack of blinding
may introduce greater bias in estimation of intervention effects
within studies with inadequate randomization than within stud-
ies with adequate randomization.
DISCUSSION
Using a collection of 2,443 randomized trials included in
228 meta-analyses, our estimates of the association between
average intervention effect estimates and routinely collected
risk-of-bias judgements for sequence generation, allocation
concealment, blinding, and incomplete outcome data confirm
that problems with randomization and a lack of blinding are,
on average, associated with a modest (around 10%) exaggeration
of treatment effect estimates. Lack of blinding appears to have
the largest influence on treatment effect estimates, and this re-
mains after adjustment for other domains. There was little evi-
dence that these biases varied according to the type of outcome
measure assessed. Although there were some differences in
the ratios of odds ratios for different outcome types in uni-
variable analyses, the 95% credible intervals overlapped, and
the differences were attenuated or disappeared in adjusted
analyses. We found little evidence that trials assessed as
being at high or unclear risk of bias for incomplete outcome
data produced systematically different estimates compared with
trials at low risk of bias for this domain, for all types of outcome
measures. Variability of treatment effects was higher in trials that
lacked blinding and had subjective outcomes, suggesting that for
such trials the direction and magnitude of bias is unpredictable.
Such variability in bias was observed both between trials
within a meta-analysis and across meta-analyses. There
Table 4. Estimated Ratios of Odds Ratios and Between–Meta-Analysis Heterogeneity in Mean Bias AssociatedWith Risk-of-Bias Judgements in
Randomized Trials andMeta-Analyses, by Type of OutcomeMeasure (Univariable Analyses (Model A)), in the ROBESStudya
Risk-of-Bias Domain andOutcome
No. of MAs
or RTs
Contributing
to Analysis
Average Bias No. of MAs
Contributing to
κEstimation
Within-MA
Heterogeneity
Between-MA
Heterogeneity
MAs RTs ROR 95%CrI κ 95%CrI φ 95%CrI
Sequence generation: high/unclear risk of bias
vs. low risk of bias
All outcomes 189 2,158 0.91 0.86, 0.98 142 0.09 0.02, 0.21 0.10 0.02, 0.20
Mortality 34 363 0.84 0.71, 1.01 27 0.13 0.01, 0.39 0.09 0.01, 0.37
Other objective/semiobjective outcome 47 523 0.99 0.87, 1.16 38 0.10 0.01, 0.31 0.14 0.01, 0.41
Subjective outcome/mixtureb 108 1,272 0.90 0.83, 0.98 77 0.08 0.01, 0.21 0.08 0.01, 0.22
Allocation concealment: high/unclear risk of bias
vs. low risk of bias
All outcomes 188 2,121 0.92 0.86, 0.98 139 0.05 0.01, 0.15 0.05 0.01, 0.17
Mortality 35 358 0.84 0.71, 1.01 27 0.07 0.01, 0.30 0.12 0.01, 0.42
Other objective/semiobjective outcome 49 524 0.96 0.86, 1.07 40 0.04 0.01, 0.14 0.05 0.01, 0.19
Subjective outcome/mixture 104 1,239 0.91 0.83, 0.99 72 0.08 0.01, 0.25 0.06 0.01, 0.20
Blinding: high/unclear risk of bias vs. low risk of
bias
All outcomes 144 1,678 0.87 0.80, 0.93 105 0.10 0.02, 0.25 0.12 0.02, 0.24
Mortality 31 327 0.83 0.72, 0.97 25 0.06 0.01, 0.26 0.06 0.01, 0.25
Other objective/semiobjective outcome 32 334 0.94 0.81, 1.10 24 0.06 0.01, 0.21 0.06 0.01, 0.28
Subjective outcome/mixture 81 1,017 0.83 0.73, 0.93 56 0.22 0.04, 0.36 0.19 0.03, 0.34
Incomplete outcome data: high/unclear risk of
bias vs. low risk of bias
All outcomes 167 1,956 0.98 0.92, 1.05 112 0.05 0.01, 0.16 0.05 0.01, 0.15
Mortality 29 303 0.92 0.79, 1.08 19 0.08 0.01, 0.32 0.06 0.01, 0.24
Other objective/semiobjective outcome 43 471 1.03 0.90, 1.19 28 0.07 0.01, 0.25 0.06 0.01, 0.25
Subjective outcome/mixture 95 1,182 0.97 0.88, 1.07 65 0.06 0.01, 0.17 0.10 0.01, 0.30
Abbreviations: CrI, credible interval; MA, meta-analysis; ROBES, Risk of Bias in Evidence Synthesis; ROR, ratio of odds ratios; RT, randomized
trial.
a For a graphical representation of these results, seeWeb Figure 3.
b
“Mixture” refers to meta-analyses in which some trials had subjective measures and some had objective measures of the same outcome (e.g.,
self-reports and laboratory measures of smoking cessation).
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was little evidence of such variation in bias for other bias do-
mains or for objectively determined outcomes. Multivariable
analyses suggested that effects of individual risk-of-bias domain
judgements were less than additive, in that estimated effects of 2
bias domain judgements together were less than the com-
bined individual effects.
To our knowledge, this study represents themost comprehen-
sive attempt to date to quantify the influence of 4 bias domains
on intervention effect estimates from randomized controlled
trials using routinely collected risk-of-bias assessments from
published Cochrane reviews. Our findings indicate that assess-
ments are associated with effect sizes, on average, for 3 of the 4
domains, providing some degree of validation of the risk-of-
bias tool. However, to interpret our findings as evidence of bias
due to the methods implemented in the trials, it is important to
consider the accuracy and reliability of these risk-of-bias assess-
ments. The assessments were made by a large number of Coch-
rane review authors with varying degrees of experience and
training, and we did not replicate assessments to determine how
appropriate they were. Although detailed guidance on how to
assess risk of bias in trials included in Cochrane reviews is
available in chapter 8 of the Cochrane Handbook (18), review
authors have reported that they find aspects of the assessment
difficult (22). Indeed, some studies have found that the assessor
agreement and interrater reliability of the risk-of-bias tool is
suboptimal (23, 24). Specifically, individual reviewers have
different criteria for judging a study to be at “low risk” of bias:
Some may be more confident about making a judgement with
less information, while others would opt for “unclear risk.”
Standard advice is that 2 assessors independently assess
risk of bias and resolve disagreements through discussion.
We presume that this advice was followed. As a safeguard
that recommended assessment methods were followed, at
least to some extent, we restricted eligibility to reviews that
had completed all 5 prescribed bias domains. It is possible
that individual review teams had their own criteria for rat-
ing a study “low-risk” for each of the domains, which may
have differed from those described in the handbook.
Table 5. Estimated Ratios of Odds Ratios and Between–Meta-Analysis Heterogeneity in Mean Bias AssociatedWith Risk-of-Bias Judgements in
Randomized Trials andMeta-Analyses, by Type of OutcomeMeasure (Multivariable Analyses (Model B)), in the ROBESStudya
Risk-of-Bias Domain and Outcome
No. of MAs
or RTs
Contributing
to Analysis
Average Bias No. of MAs
Contributing
to κEstimation
Within-MA
Heterogeneity
Between-MA
Heterogeneity
MAs RTs ROR 95%CrI κ 95%CrI φ 95%CrI
Sequence generation: high/unclear risk of bias vs.
low risk of bias
All outcomes 189 2,158 0.95 0.88, 1.03 142 0.08 0.02, 0.18 0.11 0.03, 0.22
Mortality 34 363 0.92 0.75, 1.18 27 0.14 0.02, 0.36 0.14 0.03, 0.42
Other objective/semiobjective outcome 47 523 1.06 0.90, 1.28 38 0.14 0.03, 0.33 0.20 0.04, 0.44
Subjective outcome/mixtureb 108 1,272 0.94 0.84, 1.04 77 0.08 0.02, 0.18 0.11 0.02, 0.24
Allocation concealment: high/unclear risk of bias
vs. low risk of bias
All outcomes 188 2,121 0.96 0.88, 1.03 139 0.06 0.01, 0.15 0.07 0.02, 0.16
Mortality 35 358 0.92 0.74, 1.13 27 0.11 0.03, 0.29 0.15 0.03, 0.42
Other objective/semiobjective outcome 49 524 0.94 0.81, 1.08 40 0.07 0.01, 0.18 0.09 0.02, 0.25
Subjective outcome/mixture 104 1,239 0.95 0.86, 1.07 72 0.10 0.02, 0.23 0.08 0.02, 0.20
Blinding: high/unclear risk of bias vs. low risk of
bias
All outcomes 144 1,678 0.88 0.81, 0.94 105 0.10 0.02, 0.22 0.12 0.03, 0.23
Mortality 31 327 0.87 0.73, 1.03 25 0.10 0.02, 0.26 0.10 0.02, 0.28
Other objective/semiobjective outcome 32 334 0.95 0.79, 1.12 24 0.09 0.02, 0.24 0.10 0.02, 0.34
Subjective outcome/mixture 81 1,017 0.84 0.75, 0.95 56 0.17 0.04, 0.33 0.19 0.05, 0.35
Incomplete outcome data: high/unclear risk of bias
vs. low risk of bias
All outcomes 167 1,956 1.01 0.94, 1.09 112 0.07 0.01, 0.16 0.07 0.02, 0.16
Mortality 29 303 0.99 0.82, 1.18 19 0.11 0.02, 0.31 0.10 0.02, 0.30
Other objective/semiobjective outcome 43 471 1.04 0.90, 1.21 28 0.11 0.02, 0.30 0.09 0.02, 0.26
Subjective outcome/mixture 95 1,182 1.00 0.90, 1.12 65 0.07 0.01, 0.17 0.11 0.03, 0.27
Abbreviations: CrI, credible interval; MA,meta-analysis; ROBES, Risk of Bias in EvidenceSynthesis; ROR, ratio of odds ratios; RT, randomized trial.
a For a graphical representation of these results, seeWeb Figure 4.
b
“Mixture” refers to meta-analyses in which some trials had subjective measures and some had objective measures of the same outcome (e.g.,
self-reports and laboratory measures of smoking cessation).
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In our main analyses, risk-of-bias judgements were dichoto-
mized so that “high” risk and “unclear” risk were considered
together. This allows for like-for-like comparisons with results
from most of the previous empirical studies, including our
previous study (17). Furthermore, there were few “high-
risk-of-bias” judgements, so analyses with the alternative
dichotomization of “high” versus “low” or “unclear” risk of
bias were not informative. For the domains of sequence genera-
tion and allocation concealment, a “high-risk-of-bias” judge-
ment was recorded in only 3% and 6% of trials, respectively
(Table 2). We demonstrated that Cochrane assessors frequently
reach a judgement of “unclear” risk of bias (Table 2). Inade-
quate reporting of key features of trial design is a likely explana-
tion for this high rate of uncertainty, particularly for methods of
sequence generation and allocation concealment. This obser-
vation is consistent with findings from a study by Turner et al.
(25) that allocation concealment was reported in sufficient detail
in 30% (722/2,396) of published randomized trials.
Our adjusted results for sequence generation and allocation
concealment were largely consistent with meta-analyses of all
previous meta-epidemiologic studies reported in a recent sys-
tematic review (26). Blinding and incomplete data in studies
included in that review were not assessed in the same way as in
our study and cannot be meaningfully compared with our re-
sults. Our results for average bias were slightly smaller than
those from our previous study, the Bias in Randomized and
Observational Studies (BRANDO) Study (17). This may reflect
dilution due to measurement error, arising because the risk-of-
bias assessments in the current studywere conducted by a hetero-
geneous group of Cochrane reviewers. In contrast, assessments
used in the BRANDO Study were done by teams of trained
methodologists, and data were only combined in the BRANDO
analyses where the definitions for adequate versus inadequate
study method were consistent across studies. Our finding that
the lack of blinding in trials with subjective outcomes can lead
to biased effect estimates, but the direction and magnitude of
such bias are unpredictable, also confirms a finding from the
BRANDO Study (16, 17). The main difference between find-
ings from the current study and those from the BRANDOStudy
is that here we do not see a clear difference in the magnitude of
bias according to type of outcome.
In summary, our results confirm that some aspects of the
conduct of randomized trials, particularly blinding, are associ-
ated with a modest exaggeration of treatment effects on aver-
age, but there is little evidence that the average bias differs
according to whether the outcome was subjectively or objec-
tively assessed. However, lack of blinding in trials with sub-
jective outcomes leads to increased heterogeneity and hence
unpredictable bias in effect estimates. As far as possible, clini-
cal and policy decisions should be cautious when they are
based on trials in which blinding was not reported or not feasi-
ble and outcome measures were subjectively assessed. Future
development of tools for assessing risk of bias in randomized
trials (27, 28) should reflect this observation and collect infor-
mation on the subjectivity of an outcome. Facilities for capture
of detailed routine assessments of risk of bias in randomized
trials should be made available for future meta-epidemiologic
research and could contribute to further improvement in methods
of risk-of-bias assessment.
ACKNOWLEDGMENTS
Author affiliations: Population Health Sciences, Bristol
Medical School, University of Bristol, Bristol, United
Kingdom (Jelena Savovic´, David Mawdsley, Hayley E.
Jones, Rebecca Beynon, Julian P. T. Higgins, Jonathan A. C.
Sterne); National Institute for Health Research (NIHR)
Collaboration for Leadership in Applied Health Research
and Care (CLAHRC)West, University Hospitals Bristol
NHS Foundation Trust, Bristol, United Kingdom (Jelena
Savovic´, Julian P. T. Higgins, Jonathan A. C. Sterne);
Medical Research Council (MRC) Biostatistics Unit,
University of Cambridge, Cambridge, United Kingdom
(Rebecca M. Turner); andMRC Clinical Trials Unit,
University College London, London, United Kingdom
(Rebecca M. Turner).
This work was supported by anMRC fellowship (J.S.; grant
G0701659/1) and by theMRCMethodology Research Panel
(R.M.T.; grantMR/K014587/1). J.S.’s time was partly
supported byNIHRCLAHRCWest at University Hospitals
Bristol NHSFoundation Trust. R.M.T.was supported by the
MRC (grantsMC-U105260558 andMC-UU12023/24). J.A.C.S.
was supported by aNational Institute for Health Research Senior
Investigator award (grant NF-SI-0611-10168).
The views expressed in this article are those of the authors
and not necessarily those of the MRC, NHS England, NHS
Improvement, the National Institute for Health Research, or
the United Kingdom Department of Health and Social Care.
We thank Professor Nicky J. Welton for advice about
statistical models. We thank the Cochrane Informatics and
Knowledge Management Department for providing the data.
Between January 2015 and November 2016, D.M. was
employed at the University of Bristol on an unrelated project
partly funded by Pfizer Ltd. (Tadworth, United Kingdom).
REFERENCES
1. Gluud LL. Bias in clinical intervention research. Am J
Epidemiol. 2006;163(6):493–501.
2. Sterne JA, Jüni P, Schulz KF, et al. Statistical methods for
assessing the influence of study characteristics on treatment
effects in ‘meta-epidemiological’ research. Stat Med. 2002;
21(11):1513–1524.
3. Naylor CD. Meta-analysis and the meta-epidemiology of
clinical research. BMJ. 1997;315(7109):617–619.
4. Als-Nielsen B, ChenW, Gluud LL, et al. Are trial size and
reportedmethodological quality associated with treatment
effects? Observational study of 523 randomised trials [abstract].
Presented at the 12th Cochrane Colloquium: Bridging the Gaps,
Ottawa, Ontario, Canada, October 2–6, 2004.
5. Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality
measures with estimates of treatment effect in meta-analyses of
randomized controlled trials. JAMA. 2002;287(22):
2973–2982.
6. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic
quality and discrepancies between large and small randomized
trials in meta-analyses. Ann Intern Med. 2001;135(11):
982–989.
7. Nuesch E, Reichenbach S, Trelle S, et al. The importance of
allocation concealment and patient blinding in osteoarthritis
Am J Epidemiol. 2018;187(5):1113–1122
Risk of Bias in Evidence Syntheses of Randomized Trials 1121
Downloaded from https://academic.oup.com/aje/article-abstract/187/5/1113/4604571
by MRC Biostatistics Unit user
on 21 May 2018
trials: a meta-epidemiologic study. Arthritis Rheum. 2009;
61(12):1633–1641.
8. Pildal J, Hróbjartsson A, Jørgensen KJ, et al. Impact of
allocation concealment on conclusions drawn frommeta-
analyses of randomized trials. Int J Epidemiol. 2007;36(4):
847–857.
9. Egger M, Juni P, Bartlett C, et al. How important are
comprehensive literature searches and the assessment of trial
quality in systematic reviews? Empirical study.Health Technol
Assess. 2003;7(1):1–76.
10. Herbison P, Hay-Smith J, GillespieWJ. Adjustment of meta-
analyses on the basis of quality scores should be abandoned.
J Clin Epidemiol. 2006;59(12):1249–1256.
11. Moher D, Pham B, Jones A, et al. Does quality of reports of
randomised trials affect estimates of intervention efficacy
reported in meta-analyses? Lancet. 1998;352(9128):
609–613.
12. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of
bias. Dimensions of methodological quality associated with
estimates of treatment effects in controlled trials. JAMA. 1995;
273(5):408–412.
13. Bialy L, Vandermeer B, Lacaze-Masmonteil T, et al. A meta-
epidemiological study to examine the association between bias
and treatment effects in neonatal trials. Evid Based Child
Health. 2014;9(4):1052–1059.
14. Chaimani A, Vasiliadis HS, Pandis N, et al. Effects of study
precision and risk of bias in networks of interventions: a
network meta-epidemiological study. Int J Epidemiol. 2013;
42(4):1120–1131.
15. Hartling L, HammMP, Fernandes RM, et al. Quantifying bias
in randomized controlled trials in child health: a meta-
epidemiological study. PLoS One. 2014;9(2):e88008.
16. Savovic´ J, Jones H, Altman D, et al. Influence of reported study
design characteristics on intervention effect estimates from
randomised controlled trials: combined analysis of meta-
epidemiological studies.Health Technol Assess. 2012;16(35):
1–82.
17. Savovic´ J, Jones HE, Altman DG, et al. Influence of reported
study design characteristics on intervention effect estimates
from randomized, controlled trials. Ann Intern Med. 2012;
157(6):429–438.
18. Higgins JP, Altman DG. Assessing risk of bias in included
studies. In: Higgins JP, Green S, eds.Cochrane Handbook for
Systematic Reviews of Interventions. Chichester, United
Kingdom: JohnWiley & Sons Ltd.; 2008:187–241.
19. The Cochrane Collaboration. ReviewManager (RevMan)
Software, Version 5.0. Copenhagen, Denmark: Nordic
Cochrane Centre, The Cochrane Collaboration; 2008.
20. World Health Organization. International Statistical
Classification of Diseases and Related Health Problems 10th
Revision. Geneva, Switzerland: World Health Organization;
2010. http://apps.who.int/classifications/icd10/browse/2010/
en#/. AccessedMarch 30, 2017.
21. Welton NJ, Ades AE, Carlin JB, et al. Models for potentially
biased evidence in meta-analysis using empirically based
priors. J R Stat Soc Ser A Stat Soc. 2009;172(1):119–136.
22. Savovic´ J,Weeks L, Sterne JA, et al. Evaluation of the Cochrane
Collaboration’s tool for assessing the risk of bias in randomized
trials: focus groups, online survey, proposed recommendations
and their implementation. Syst Rev. 2014;3:37.
23. Armijo-Olivo S, Ospina M, da Costa BR, et al. Poor reliability
between Cochrane reviewers and blinded external reviewers
when applying the Cochrane risk of bias tool in physical
therapy trials. PLoS One. 2014;9(5):e96920.
24. Hartling L, HammMP,Milne A, et al. Testing the risk of bias
tool showed low reliability between individual reviewers and
across consensus assessments of reviewer pairs. J Clin
Epidemiol. 2013;66(9):973–981.
25. Turner L, Shamseer L, Altman DG, et al. Consolidated
Standards of Reporting Trials (CONSORT) and the
completeness of reporting of randomised controlled trials
(RCTs) published in medical journals. Cochrane Database
Syst Rev. 2012;11:MR000030.
26. PageMJ, Higgins JP, Clayton G, et al. Empirical evidence of
study design biases in randomized trials: systematic review of
meta-epidemiological studies. PLoSOne. 2016;11(7):e0159267.
27. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised
trials. BMJ. 2011;343:d5928.
28. Higgins JP, Sterne JA, Savovic´ J, et al. A revised tool for
assessing risk of bias in randomized trials. Cochrane Methods.
2016;10(suppl 1):29–31.
Am J Epidemiol. 2018;187(5):1113–1122
1122 Savovic´ et al.
Downloaded from https://academic.oup.com/aje/article-abstract/187/5/1113/4604571
by MRC Biostatistics Unit user
on 21 May 2018
